News | October 05, 2010

New Benchmarks Established for EP Device Replacement Decisions

October 5, 2010 – Data from a prospective study show physicians may benefit from knowing complication rates associated with pacemaker or implantable cardioverter defibrillator (ICD) generator replacement and upgrade procedures. Results from the REPLACE Registry also established new benchmarks for making electrophysiology (EP) device replacement decisions.

The results will be published in the Oct. 19 issue of Circulation and have been published online. The article presents data from the first prospective multicenter study designed to evaluate the rate of complications from cardiac rhythm management (CRM) device replacement and upgrade from all CRM manufacturers.

“REPLACE is the first prospective multicenter trial to examine a broad range of complications related to generator replacement. The two patient populations studied included patients who needed only a generator replacement and those who required a lead addition or revision for advanced therapy. While the major complication rate for a generator replacement alone was modest, the risk associated with upgrade procedures was markedly higher,” said Jeanne Poole, M.D., director of electrophysiology at the University of Washington, and national principal investigator of the REPLACE Registry.

Poole added, “Important take home messages include the development of devices with long battery life to minimize the lifetime surgical risk for a patient and thoughtful consideration of the proper choice of device for each patient. Using the fewest leads necessary for the clinical need of the patient is important, and yet, our data would also support performing indicated complex procedures before the development of advanced end-stage medical and cardiac disease, situations in which the risk may be prohibitive.”

Patients were initially categorized based on whether the generator replacement procedure did not (cohort 1) or did (cohort 2) include a lead addition or revision. Definitions for major and minor complications were predefined and an independent committee reviewed all reported events.

“REPLACE provides important information regarding the next phase of life for patients with cardiac implantable electronic devices,” said Marye Gleva, M.D., associate professor of medicine, Washington University School of Medicine, St. Louis, Mo.

For more information:

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Overlay Init